Sugi Predict

Sugi Predict / Compounds / SCHEMBL633161

SCHEMBL633161

SCHEMBL633161

CCC(=O)c1cccc(F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.61
▸ CES1 P23141 2/20 0.61
▸ MAPT P10636 4/20 0.57
▸ GAA P10253 1/20 0.57
▸ PARP1 P09874 1/20 0.57
▸ NPC1 O15118 4/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ HPGD P15428 3/20 0.54
▸ HTT P42858 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ TSHR P16473 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ALOX12 P18054 1/20 0.54
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10389972 0.85 SMN1; SMN2 (0.54) CES2CES1MAPTGAANPC1
SCHEMBL906035 0.85 CES2 (0.57) CES2CES1MAPTPARP1NPC1
SCHEMBL29987428 0.83 MEN1 (0.72) CES2CES1MAPTPARP1NPC1
SCHEMBL29508072 0.82 HTR7 (0.64) CES2CES1MAPTPARP1NPC1
SCHEMBL3712920 0.82 CES2 (0.63) CES2CES1MAPTPARP1NPC1
SCHEMBL364308 0.82 CES2 (0.63) CES2CES1MAPTPARP1NPC1
SCHEMBL29772245 0.82 CES2 (0.63) CES2CES1MAPTPARP1NPC1
SCHEMBL29368006 0.82 CES2 (0.63) CES2CES1MAPTPARP1NPC1
SCHEMBL3022836 0.81 MEN1 (0.59) CES2CES1MAPTPARP1NPC1
SCHEMBL3026885 0.81 MEN1 (0.59) CES2CES1MAPTPARP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106083686-B The method of alpha-brominated acetophenone oxime ether synthesis 2,4- diaryl pyrrole class compound 苏州大学 2019-01-22 — — CN claimed
CN-105801550-A Novel benzopyran kinase modulators 理森制药股份公司 2016-07-27 — — CN claimed
CN-105541575-A Synthetic method of fluvastatin drug intermediate 2-chloro-1- (4-fluorophenyl) ethanone CHENGDU CARDIFF SCIENCE AND TECH CO LTD 2016-05-04 — — CN claimed
CN-102797043-B Medicinal molecular fragment library and construction process thereof Tianli (Tianjin) Technology Co., Ltd. (CN) 2015-11-25 — — CN claimed
CN-102797043-A Medicinal molecular fragment library and construction method thereof CBB NETWORK CO LTD 2012-11-28 — — CN claimed
US-7608740-B2 Method of synthesizing key intermediates for the production of camptothecin derivatives Avra Laboratories Pvt. Ltd (IN) 2009-10-27 — — US claimed
EP-4748834-A1 NOVEL HYDRAZONE DERIVATIVE AND AGENT FOR AGRICULTURAL AND HORTICULTURAL USE CONTAINING SAME AS ACTIVE INGREDIENT Agro-Kanesho Co., Ltd. (JP) 2026-05-27 — — EP disclosed
CN-119390551-A Method for realizing methoxymethylation under photocatalysis condition 浙江工业大学 2025-02-07 — — CN disclosed
WO-2025018390-A1 NOVEL HYDRAZONE DERIVATIVE AND AGENT FOR AGRICULTURAL AND HORTICULTURAL USE CONTAINING SAME AS ACTIVE INGREDIENT アグロカネショウ株式会社 2025-01-23 — — WO disclosed
EP-4400500-A1 HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2024-07-17 — — EP disclosed
US-20230151025-A1 SUBSTITUTED THIAZOLOPYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES BAYER AG (DE) 2023-05-18 — — US disclosed
EP-3911660-B1 PROCESS FOR PREPARATION OF 2-AMINO-5-HYDROXY PROPIOPHENONE LAURUS LABS LTD (IN) 2023-05-10 — — EP disclosed
EP-3911660-B1 PROCESS FOR PREPARATION OF 2-AMINO-5-HYDROXY PROPIOPHENONE LAURUS LABS LTD (IN) 2023-05-10 — — EP disclosed
EP-0583271-A1 ARYLMORPHOLINE, PREPARATION AND USE THE WELLCOME FOUNDATION LIMITED (GB) 1994-02-23 — — EP disclosed
WO-1992018489-A1 ARYLMORPHOLINE, PREPARATION AND USE THE WELLCOME FOUNDATION LIMITED (GB) 1992-10-29 — — WO disclosed
US-5103022-A Reacting dl-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino -1-propanone with l-acetylphenylglycine to form corresponding diastereomeric salt, deposition, isolation of l-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1992-04-07 — — US disclosed
US-5057535-A Muscle relaxants NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1991-10-15 — — US disclosed
US-4690931-A IN TREATMENT OF ANOXIA OR BRAIN DAMAGE SYNTHELABO (FR) 1987-09-01 — — US disclosed
CN-86108538-A The inhibition of 5-lipoxygenase pathway — 1987-07-29 — — CN disclosed
EP-0200942-A2 New derivatives of an aminoketone NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1986-11-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151025-A1 SUBSTITUTED THIAZOLOPYRIDINES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES TST, DDT, GMDS CES2 364/4885CES1 658/4885MAPT 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.